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INTRODUCTION
Central Nervous System (CNS) infections carry a
high morbidity and mortality rate. They affect any
part of the CNS (cerebral parenchyma, meninges,
spinal cord) and can be caused by infectious
organisms such as bacteria, fungi, parasites, viruses,
and prions resulting in inflammation. Accurate
diagnosis and prompt treatment of many CNS
infections is difficult even in the most sophisticated
medical centers.  In resource-limited settings seen in
developing countries, the rapid diagnosis that is
essential for effective treatment is even more
challenging.
The Human Immunodeficiency Virus (HIV) is the
causative agent of the Acquired Immunodeficiency
Syndrome (AIDS).  At the end of 2003, an estimated
34.6 - 42.3 million people worldwide were living with
HIV, of whom two thirds live in Africa (1, 2). The
term AIDS was first used in 1981 to describe a
combination of opportunistic infections and tumours
occurring in young homosexual men who were dying
from infections that a healthy immune system would
easily combat (3). Today, the pandemic spread of HIV
and lack of antiretroviral therapy distribution in
developing countries is contributing to AIDS-related
opportunistic infections, including those affecting the
central nervous system.
The profile of CNS infections in Sub-Saharan
Africa has changed as a result of the HIV epidemic.
For example, a study of 284 patients hospitalized with
meningitis in Johannesburg, South Africa, found
tuberculous meningitis (TBM) to be the most
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common diagnosis (25.4%), followed by acute
bacterial meningitis (22.5%), viral meningitis
(14.1%), and cryptococcal meningitis (13%) with
more than 40% in-hospital mortality (4). In a study of
200 patients diagnosed with meningitis in Harare,
Zimbabwe, cryptococcal meningitis was the most
common diagnosis (45%), followed by mononuclear
meningitis (27%), acute bacterial meningitis (16%),
and TBM (12%); with in-hospital mortality also
greater than 40% (5). These high in-patient CNS
infection-related mortality rates in resource-limited
settings call for the medical community to address the
management of CNS infections.  In the past, simple
algorithmic approaches have led to improved patient
outcomes for life threatening infections such as
pneumonia in HIV-1 patients (6). It is important to
design a similar efficient algorithmic approach for the
timely diagnosis and treatment of CNS infections,
especially in the face of the growing HIV/AIDS
epidemic, in settings where access to sophisticated
diagnostic tools is not readily available. 
Uganda is a country located in East Africa, with a
population of 26.4 million (7). After independence
was gained from Britain in 1962, the oppressive
dictatorial regimes of Idi Amin and Milton Obote, as
well as the poverty and the onset of HIV/AIDS
epidemic, took an enormous toll on Ugandan society
(8, 9). In 1986, Museveni became the president, and
by the 1990's, the stability in the country started being
regained. However, despite a relatively stable
political state at the macro level, widespread intrinsic
poverty continues at the microeconomic level,
especially in the rural areas, where the majority of the
population lives. Today, more than 50% of the
population is attempting to survive on less than 1$US
per day and AIDS is the leading cause of death in the
15-49 age group (8). The health sector in Uganda is
underfunded and the accessibility to health care
services is inadequate with 18,700 people per doctor
and 870 people per hospital bed (10). This situation
amounts to a heavy burden of preventable diseases
and a low life expectancy [45 years in 2002 (7)].
Uganda, however, has been repeatedly reported as one
of the only African countries where HIV/AIDS
prevalence is decreasing, with a fall in the national
prevalence from 13% in the early 1990s to 4.1% by
the end of 2003 (1).
Mulago Hospital is a national referral and teaching
hospital in Kampala, the capital city of Uganda. The
hospital general medical wards admit on average 30-
50 patients a day, and overcrowding is a problem.
Accessbility of essential drugs and supplies is highly
variable. The most common medical conditions on the
general wards include AIDS-related infections and the
most common causes of death include CNS
infections, pneumonias, and tuberculosis (11).
The Academic Alliance for AIDS Care and
Prevention in Africa (AAACP) is a not-for-profit
organization formed in June 2001 by a group of
physicians and scientists from Makerere University in
Kampala, Uganda and the Infectious Disease Society
of America with HIV/AIDS care experts from North
America (12).  The goal of the AAACP is to fight
Africa's biggest health threat, HIV/AIDS, and to
improve the quality of medical care for the 27 million
HIV-infected people living in sub-Saharan Africa
(13).  The organization supports the Infectious
Disease Center (IDC) at the Mulago Hospital and is
involved in many ongoing studies funded by the Bill
& Melinda Gates Foundation. The aim of one such
study is to design an algorithmic approach that
maximizes available resources to enhance the
outcome of patients presenting with CNS symptoms.
The study's goal is to improve the accuracy and speed
of diagnosis and thereby lead to more prompt disease-
specific treatment and a decrease in the in-patient
hospital stay when compared to the current standard
of care.  Four case reports of patients from this study
are presented in this article, followed by a review of
the pathology, diagnosis, and treatment of TBM, CM,
toxoplasmosis, and PCNSL in immunocompromised
patients.
LITERATURE REVIEW
Opportunistic infections are common complications
of advanced immunodeficiency in individuals with
HIV-1 infection. Following involvement of thelung,
the central nervous system is the second most
commonly affected organ (23). Neurological disease
is the first manifestation in 10-20% of symptomatic
HIV-infected individuals, presenting in 39-70%  of
HIV-infected patients and found at autopsy in up to
79% of AIDS patients (20, 21, 23, 24, 26, 27).
Neurological complications associated with HIV-1
infection may be primary (HIVdementia,
inflammatory demyelinating polyneuropathy,
cerebrovascular disease) or secondary (Tuberculosis,
T. gondii, Cryptococcus neoformans, or Nocardia
infections, Primary CNS Lymphoma) (20).
The diagnostic approach to an
immunocompromised host with CNS infection
depends on the analysis of the patient's clinical
manifestations of CNS disease, including the
acuteness or sub-acuteness of the disease. Most
patients with CNS infections may be grouped into
those with meningeal signs, or those with mass
lesions. Meningitis and encephalitis tend to present
more acutely whereas CNS mass lesions tend to
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present subacutely or chronically. Meningitis of
bacterial, cryptococcal, or tuberculous origin can be
diagnosed from stain, culture, or serology of the CSF.
In contrast, patients with CNS mass lesions usually
require a tissue biopsy to arrive at a specific etiologic
diagnosis (28), making it a very challenging diagnosis
in a resource-limited setting. 
1) Tuberculous Meningitis (TBM)
Approximately 2 billion people in the world are
infected with tuberculosis, yet the risk of developing
clinical tuberculosis (TB) post-infection is only 10%
in an immunocompetent individual; However, HIV
coinfection increases this risk over 3 times (15).
Central nervous system TB occurs in 2% of all
patients with TB and in 10% of those with AIDS, and
can be the first manifestation of AIDS in 20% of HIV
positive patients (29, 30). The total number of TB
cases is increasing. Tuberculosis is caused by
infection with Mycobacterium tuberculosis, through
droplet inhalation. Infection is localized within
alveolar macrophages and causes a brief but
significant bacteremia, seeding bacteria to other
organs, including the meninges or brain parenchyma,
forming sub-ependymal foci called Rich foci. During
tuberculous meningitis (TBM) development, a Rich
focus ruptures into the subarachnoid space, resulting
in a local T-lymphocyte dependant immune response
that heralds the onset of meningitis (15). Clinical
findings include fever (54%), headache (50%), altered
mental status (42%), cough (33.3%), nausea/vomiting
(21%), meningismus (17%), and seizures (4%) (30).
Diagnosis is dependent on lumbar puncture (LP) and
CSF analysis (the gold standard). However, culture is
insensitive and very slow (taking up to 6-8 weeks) to
aid clinical decisions (6, 30). The search for acid fast
bacilli (AFB) by direct Ziehl-Neelsen staining of the
CSF represents the best rapid laboratory diagnostic
technique (16), however, this lacks sensitivity as
AFBs are seen in only 10-20% of patients with TBM
(15, 16). Lymphocytosis is between 100-1000
cells/mm3, with raised CSF protein and reduced CSF
glucose in 70% of patients (15).  CT and MRI imaging
of the brain is significant for meningeal enhancement,
communicating hydrocephalus, infarcts in territory of
middle cerebral artery, edema, and tuberculomas
(solitary or multiple), with the basal ganglia most
often affected (30). Treatment consists of four-drug
combination chemotherapy including isoniazid,
rifampicin, pyrazinamide, and ethambutol or
streptomycin for the first two months (15, 30). The
duration of the continuation phase varies between 10-
22 months (15, 31) and includes rifampicin and
isoniazid only or all four drugs (15). A corticosteroid
such as dexamethasone can be added as an adjuvant as
it may reduce the effects of inflammation, long term
neurological sequelae, and mortality (32). 
Clinical manifestations of TBM are variable, but
are not altered when comparing HIV-infected patients
to non-infected individuals (29).  The key challenge
of TBM diagnosis is distinguishing it from bacterial
meningitis. CFS cell counts, glucose and protein
results can be similar in partially treated bacterial
meningitis and early TBM, making a clear diagnosis
often impossible (15). Patients with TBM, however,
present with a longer history that can include cranial
nerve palsies; clear CSF with a moderate number of
lymphocytes and neutrophils with an increased
protein concentration; a low ratio of CSF: blood
glucose; CT scan consistent with TBM; a chest
radiograph that can be consistent with active
pulmonary TB; and good response to antituberculosis
chemotherapy, providing additional support for the
diagnosis of tuberculosis (16).
Among HIV-infected patients, TBM mortality
approaches 80% (30).  Rapid diagnosis and treatment
can prevent death and neurological morbidity.
However, current laboratory methods are insensitive
and slow, and new techniques, such as polymerase
chain reaction (PCR), are not suitable for widespread
use in the developing world. In addition, multiple
drug resistant strains of M. tuberculosis are emerging,
making therapy a further challenge in the treatment of
this disease in any setting.
2) Cryptococcal Meningitis (CM)
Of the systemic fungal infections in HIV-1 infected
patients, cryptococcal meningitis (CM) is the most
common and its incidence among AIDS patients
varies between 10% in the United States and Europe
and 30% in sub-Saharan Africa (24, 33). In Uganda,
advanced HIV-related immunosuppression is the
strongest independent risk factor for cryptococcal
disease, and in HIV-infected adults it is the leading
contributor to death (34). CM is caused by infection
with the saprophytic yeast Cryptococcus neoformans,
an encapsulated fungus acquired from the
environment via inhalation, affecting patients with
CD4 T-lymphocyte counts of less than 100 x106
cells/L (24). Pathology of CM reveals basilar,
nonexudative chronic meningeal inflammation as
well as cryptococcomas and microabscesses in the
basal ganglia region. In immunocompetent patients,
CM presents with neurologic manifestations without
evidence of systemic infection, most commonly
presenting with meningismus and photophobia (24).
In HIV-positive patients however, presentation
includes non-specific signs and symptoms such as
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fever (58%), headache (32%), cough (23%),
meningismus (13%), depressed level of consciousness
(5%), and confusion (4%) (34).  In addition, elevated
intracranial pressure (ICP) occurs in over 50% of
HIV-infected patients with CM without
accompanying hydrocephalus or cerebral edema.
Diagnosis is based on detection of the cryptococcal
capsular polysaccharide antigen (CrAg) in the CSF
and serum, CSF India Ink stains, and culture of the
organism in CSF (which is considered to be the
definitive diagnosis of CM) (21, 24). Treatment is of
utmost importance as mortality from cryptococcal
disease is inevitable in the absence of appropriate
therapy. Treatment includes induction with
intravenous Amphoteracin B combined with 5-
flucytosine for two weeks, followed by consolidation
therapy with fluconazole for 8 weeks (24).  In patients
with elevated ICP, serial lumbar punctures are
indicated. If refractory to serial LPs, less conservative
measures such as lumbar drains and lumbar peritoneal
shunts can be employed to normalize the ICP (25).
There is limited resistance associated with
fluconazole use and it may therefore be used for
lifelong secondary prophylaxis to prevent re-infection
with different strains of C. neoformans (33). In
addition, exposure to fluconazole for more than 90
days proved to reduce the risk of CM by 82% and it
can therefore be used for primary prophylaxis when
CD4 T-lymphocyte count falls below 200 x106 cells/L
(34). However, in an African setting, where access to
appropriate laboratory facilities and funds is limited,
CD4 T-lymphocyte levels are of little value. CM is a
distressing and painful illness that is compounded by
rudimentary palliative care and difficulties in
prescribing opiate analgesia in much of Africa.  In
addition, the absence of antiviral therapy further adds
to the challenges of preventing and fighting the
disease. Thus, in an African setting a cryptococcal
vaccine would be the most relevant approach to the
prevention of CM.
3) Cerebral Toxoplasmosis
Cerebral toxoplasmosis is the most common
cerebral mass lesion in HIV-1 infected patients (20,
24, 36). It is caused by infection of an intracellular
parasite, T. gondii, whose difinitive host is the cat. As
cats excrete oocysts, the oocysts sporulate and
become infectious tissue cysts. Humans can acquire
the parasite, leading to latent infection.  It is estimated
that 10-40% of HIV-1 infected patients are
seropositive for anti-Toxoplasma antibodies and 25-
50% of patients experience symptomatic infection in
the absence of antimicrobial prophylaxis (24).
Cerebral toxoplasmosis is caused by reactivation of
latent infection as a result of progressive loss of
cellular immunity, developing when CD4+ T-
lymphocyte count falls below 100 x106 cells/L (20,
24). Reactivation causes multifocal necrotizing
encephalitis and surrounding inflammation, most
commonly in the frontal and parietal areas of the
brain, especially in the cortico-medullary junction,
the basal ganglia, and the thalamus, involving both
the gray and/or white matter (20, 24). Disease in
symptomatic patients manifests by headache,
confusion, fever, lethargy, seizures, cranial nerve
palasies, psychomotor changes, hemiparesis and/or
ataxia. Diagnosis can be made based on the presence
of anti-toxoplasma antibodies in the blood (although
not specific) or in the CSF. In contrast, a more
specific (although not very sensitive) diagnostic
method is PCR amplification of T. gondii-DNA (24).
Standard tests of CSF specimens in patients with
toxoplasmosis are nonspecific and are often normal
(20). Computed Tomography (CT) and MRI imaging
findings include multiple ring-enhancing lesions
[although 27% of patients have a single lesion on
imaging studies (22)] with surrounding edema and
mass effect, with MRI imaging being more sensitive
(37). A definite diagnosis requires demonstration of
tachyzoites in a biopsy specimen of the brain (20).
Treatment of toxoplasmosis consists of sulfadiazine
in combination with pyrimethamine with added
folinic acid supplementation to counter the
hematopoietic toxicity of pyrimethamine. If
sulfonamides cannot be tolerated, a combination of
clindamycin and pyrimethamine can be used.
Response to anti-toxoplasmosis therapy observed
within the first 2-3 weeks of treatment is also used for
diagnostic purposes (21, 28). Induction therapy is
given for 6 week, followed by maintenance therapy
with lower doses of the same regimen (20). Primary
prophylaxis with trimethoprim-sulfamethoxazole is
recommended for T. gondii seropositive patients with
CD4+ T-lymphocyte counts of 100 x106 cells/L or less
(24).  However, despite increasing prescription of
primary prophylaxis (which is not always successful),
it is likely that toxoplasmosis will remain an
important source of neurologic morbidity in AIDS
patients, and continue to be a presenting illness in
previously unidentified HIV-infected individuals (36).
4) Primary CNS lymphoma (PCNSL)
Primary CNS lymphoma (PCNSL) is the second
most common cause of AIDS-related focal brain
lesions after cerebral toxoplasmosis (20, 24). It is an
extranodal, non-Hodgkin B-cell type neoplasm that is
1000-3900 times more common in HIV-1 infected
patients than in the general population, especially in
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patients with CD4 T-lymphocyte counts below 50
x106 cells/L (24, 38). Furthermore, survival of
patients with AIDS-associated PCNSL is significantly
less than in non-AIDS-associated cases (2.6 vs 18.9
months) (39). Almost 100% of AIDS-related PCNSL
contain Epstein-Barr virus (EBV) genomic DNA
within the lymphoma cells, an uncommon finding in
tumours from immunocompetent patients (39). EBV
infects B-cells and causes clonal expansion of
infected cells.  Normally, regulation of B-cell growth
is mediated by T-lymphocytes. Therefore, quantitative
abnormalities in T-lymphocytes in HIV-1 infected
patients may account for uncontrolled EBV-induced
B-cell proliferation and subsequent neoplastic
transformation in an immunologically privileged site,
such as the CNS (39). The clinical presentation of
PCNSL in patients with AIDS includes an
approximately two-month history of altered mental
status (48-60%), seizures (15-41%), focal neurologic
deficits or sensory findings (31-78%), headache and
evidence of increased intracranial pressure (5-45%),
as well as manifestations of AIDS such as
opportunistic infections (20, 24). Neuroimaging
findings (CT or MRI) may reveal solitary or
multifocal hypodense enhancing lesions (in a ring or
a homogeneous pattern) exhibiting mass effect with
surrounding edema (20, 24). A majority of the
tumours are located supratentorially and adjacent to
CSF pathways (in the corpus collosum, cerebrum,
basal ganglia, and occasionally in the brain stem)
(20).   CSF analysis is rarely helpful but it is used for
excluding other diagnoses. However, PCR
amplification of the CSF for EBV DNA may serve as
a tumor marker for PCNSL and it is the standard of
care in patients with CT findings of focal enhancing
CNS-lesions (20). The most commonly used
treatment modality is external beam radiation therapy,
and standard whole brain radiation (4000-6000 cGy)
should be used (24). However, it is important to note
that this treatment modality can lead to long-term
cognitive dysfunction as a result of progressive
cerebral demyelination (39). Radiotherapy in patients
with non-AIDS-associated PCNSL can be
supplemented with steroid chemotherapy, which
works on the principle of its lymphotoxic effect (39).
Surgical resection is usually not possible due to the
fact that the tumour is most often multifocal and
resection does not improve prognosis (20). It is
important to note that empiric anti-toxoplasmosis
therapy is the first-line treatment approach to most
HIV-1 positive patients with focal brain lesions and
should thus be employed in patients presenting with
PCNSL-related pathology prior to administration of
PCNSL-specific treatment (24). Remission of AIDS-
related PCNSL has been described in association with
highly active antiretroviral therapy (HAART) (40).
Unfortunately, antiretroviral therapy is not widely
available in many areas of the world most affected by
the burden of HIV infection, and its availability and
use in developing countries will have a crucial
influence on the incidence and prognosis of diseases
such as PCNSL.
5) TBM vs Toxoplasmosis vs PCNSL
The diagnosis of neurological diseases is not
always evident as it is often very difficult to
distinguish, especially between toxoplasmosis and
PCNSL. In patients with mass effect on CT scans, the
diagnosis can be aided by examining anti-Toxoplasma
antibodies (toxoplasmosis probability is 0.87 if
seropositive and probability of PCNSL is 0.74 if
seronegative).  PCR amplification of the CSF for T.
gondii-DNA or EBV-DNA increases the probability
of toxoplasmosis or PCNSL to 0.96 if the test is
positive (41). Furthermore, when the differential
diagnosis of a CNS mass lesion based on
neuroradiologic characteristics is between TBM,
toxoplasmosis, and PCNSL, a trial of empiric therapy
is warranted (28). Antitoxoplasmosis therapy may be
initiated and usually results in clinical improvement
after 2-3 weeks of therapy. Nonresponse to
antitoxoplasmosis therapy would justify an empiric
trial of antituberculous therapy.  Lack of response to
anti-Toxoplasma and antituberculous therapy should
suggest a noninfectious etiology, such as primary
CNS lymphoma, for which treatment in a resource-
poor setting is limited, especially in a setting where
access to antiretroviral therapy is available to a
minority of AIDS patients.
PATIENT CASE PRESENTATIONS
1) A Socially-Challenged Case - Algorithm Arm
KE, a 23-year-old male prisoner, was referred to
Mulago Hospital for specialized treatment after
failure to improve during 3 days of management at the
Murchison Bay Prison Referral Hospital where he
was admitted with a history of new onset of left upper
limb weakness. He had a past history of pulmonary
tuberculosis and was on the continuation phase of
anti-TB treatment. His present history included two
weeks of a mild headache, convulsions, confusion,
and limb weakness that was most pronounced in the
left upper limb. On admission, he had healed scars
suggestive of past generalized maculo-papular rash
and oralcandidiasis.Hewas afebrile, had no nausea or
vomiting, and had an unremarkable cardiorespiratory
physical exam. His Glasgow Coma Scale (GCS) was
15/15, Karnofsky score was 70%, neck was supple,
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Kerning's sign was negative, and papilledema was
absent.  His motor exam was significant for left upper
limb monoplagia (power of 0/5), generalized brisk
reflexes, right flexor plantar response, unresponsive
left plantar response, and a normal sensory exam.
Clinical studies were negative for serum Cryptococcal
antigen (sCrAg), and a rapid HIV test was positive. A
lumbar puncture (LP) was not performed due to focal
neurological signs. The presumptive diagnosis was
cerebral toxoplasmosis with a differential diagnosis of
bacterial meningitis and tuberculous meningitis
(TBM) secondary to history of tuberculosis with
uncertain compliance to treatment.  He was started on
empiric treatment for toxoplasmosis (1440 mg Septrin
po q8h), bacterial meningitis (2g IV ceftriaxone QD),
continued oral anti-TB treatment (Isoniazid and
Ethambutol), and phenytoin (300 mg po QD). The
patient's condition progressively declined and on the
5th day after admission, he rapidly deteriorated
clinically with a GCS of 7/15, slowing respiration,
and right upper limb held in decorticate position.  At
that time, the ward team performed an LP.
Cerebrospinal fluid (CSF) analysis revealed 10
cells/cm3, protein 200 mg/dL, Gram and Ziehl-
Neelsen (ZN) stains were negative as was the
bacterial culture. A CT scan was done on the same day
and showed an extensive ill-defined, non-enhancing
hypodense lesion involving most of the right parietal
lobe with global sulcial effacement, right lateral
ventricle compression with 0.9 cm mid-line shift to
the left, all suggesting an inflammatory cerebral
lesion with massive brain edema with imminent
danger of infratentorial coning (figure 1).  Based on
the LP and CT results, diagnoses included
toxoplasmosis, TBM, and cerebral brain abscess.
Management was modified to include a corticosteroid
(8mg IV dexamethasone q8h), a diuretic (40mg IV
furosemide q12h), and the insertion of a nasogastric
tube.  Despite continued treatment for the presumed
differential diagnoses, the patient continued to
deteriorate and died on the 15th day after admission.
The case demonstrates several challenges unique to
a resource-limited setting. At the Mulago hospital,
patients are cared for by relatives, who feed the
patient and provide basic nursing care, including
bathing, changing, and turning the patient. For the
prisoner, social support was poor as he received
limited care from prison staff. For example, upon
deterioration, the patient could no longer accept solid
food. The prison changed the food to porridge, but its
supply was not regular. Also, the basis for the original
diagnosis of pulmonary TB was not certain and the
patient's compliance was unknown.
In conclusion, the patient presented with
progressively worsening signs of focal neurological
deficits. He was managed for toxoplasmosis, TBM,
and a bacterial cerebral abscess. The neurological
clinical and diagnostic findings were suggestive of a
progressive cerebral lesion that was unresponsive to
treatment and complicated by limited social support,
leading to death on the 15th day after admission.
2) A complicated diagnosis - Algorithm Arm
NR, a 32-year-old female, was brought into the
Mulago Hospital by her neighbours who found her
"unconscious" in her house. They reported that she
complained of feeling "unwell" for the past 3 days.
On admission, she was found to be semicomatose
with a fever of 38.4oC, stertorous respiration, healed
scars suggestive of maculo-papular rash (unknown
serostatus), GCS was 11/15, neck was stiff, Kerning's
sign indeterminable, generalized brisk reflexes,
normal muscle bulk, and no papilledema. Her
cardiorespiratory exam was normal. Upon arrival to
the casualty department, she was managed for
cerebral malaria (600 mg IV quinine in a 500ml 5%
dextrose solution). She was then transferred to the
emergency room, where the working diagnosis was
bacterial meningitis. IV quinine was stopped and IV
ceftriaxone (2g QD) was started. An LP was done
within 24 hrs of admission.  Results were obtained on
the second day of admission and showed 800
cells/cm3 (predominately lymphocytes), protein 80
mg/dL, negative India ink, Gram stain, and ZN stain,
and no bacterial growth on overnight culture. Based
on these findings, the working diagnosis changed to
tuberculous meningitis. Oral anti-TB drugs were
started (two months intensive phase of 800mg
Ethambutol, 450 mg Rifampicin, 1.2 g Pyrazinamide,
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Figure 1. CT scan (post-contrast) of patient KE showing an extensive
ill-defined, non-enhancing hypodense lesion involving most of the
right parietal lobe with global sulcial effacement, right lateral
ventricle compression with 0.9 cm mid-line shift.  Findings are
suggestive of an inflammatory cerebral lesion with massive brain
edema with imminent danger of infratentorial coning.  Possible
differential diagnoses include toxoplasmosis, TBM, and cerebral
brain abscess.CNS Infections 45
300 mg Isoniazid QD) and ceftriaxone was stopped.
Patient improved over the subsequent 7 days with a
GCS of 15/15. However, despite improvement, the
patient complained of continued mild headache and
had a spiking fever and therefore remained under
hospital care. On the 15th day after admission, she
started deteriorating; she had a worsening headache,
fluctuating mental status, papilledema, and no focal
neurological signs. An LP was repeated despite
increased intracranial pressure (in the setting of
Cryptococcal meningitis, lumbar punctures are not
contraindicated and therapeutic LPs are often done
despite increased intracranial pressure - see
discussion).  The analysis revealed turbid CSF, 250
cells/cm3 (predominately lymphocytes), protein 120
mg/dL, Gram stain 2+ encapsulated yeast cells, 1+
gram negative rods, 2+ leukocytes, India ink 2+ for
encapsulated yeast cells, negative ZN stain, culture
isolated 2+ Cryptococcus neoformans. The diagnosis
changed to mixed Cryptococcal meningitis (CM) and
gram-negative bacterial meningitis.  Treatment was
modified to IV Amphoteracin B (50 mg QD) for 14
days, IV ceftriaxone (2g QD) for 10 days.  After the
4th day of treatment, the patient dramatically
improved and was discharged after the completion of
Amphoteracin B treatment, 36 days after admission.
The case demonstrates many findings common in
Uganda. Firstly, it illustrates an example of the most
common pathology in patients presenting with fever,
plasmodium falciparum infection (malaria).  The case
also shows the diagnostic challenges associated with
the initial improvement response observed with anti-
TB treatment which is then followed by deterioration
as is demonstrated by the altered LP results.  Similar
improvement of symptoms after anti-tuberculosis
treatment has been reported, with the reason for
improvement is not understood (14). Additionally, the
case is an example of clinical diagnosis of HIV using
the criteria of a major opportunistic infection (CM).
The patient received voluntary counseling and was
referred to the infectious disease clinic after
discharge.  It is important to note that if the patient
had been in the standard of care arm of the study, as
opposed to the algorithmic arm, a repeated LP would
not have been performed because the patient initially
improved with anti-TB drugs. In the algorithm arm,
patient deterioration calls for a repeated LP.
3) Tuberculous Meningitis - Algorithm Arm
NM, a 35-year-old female, presented to the Mulago
Hospital with a 14-day history of gradual onset of
headache and a 6-month history of nuchal pain,
photophobia, recurrent high-grade fevers, malaise,
and no past history of treatment for opportunistic
infections.  The 6-month history of poor health
concerned NM's relatives and prompted them to do an
HIV test without NM's consent or awareness 3 weeks
prior to admission, the results of which were positive.
On admission, she was delirious, her GCS was 15/15,
her Karnofsky score was 60%, Kernig's sign was
positive, and her neck was stiff.  Papilledema could
not be assessed because the patient was delirious and
resistant. The physical exam revealed generalized
hyperreflexia (3+) with normal power, tone, and
sensation in all 4 limbs, and bilaterally down-going
toes. The remainder of the physical exam was
unrevealing. Based on the findings, the working
diagnosis was acute bacterial meningitis (ABM).  An
LP was done within 24 hours of admission and the
patient was started on empirical IV ceftriaxone (2g
QD). On the second day of admission, the patient
deteriorated clinically with the development of
aphasia and a GCS of 9/15. She continued being
managed for ABM until the third day of admission
when LP results were obtained.  The results showed a
white blood cell count of 250 cells/ml3
(predominantly lymphocytes), protein of 120 mg/dL,
India ink and Gram-stain were negative, and the ZN
stain was significant for 1+ acid fast bacilli (AFB), 2+
WBC, with cultures to follow.  The diagnosis changed
to tuberculous meningitis (TBM) and she was started
on a 2-month induction treatment for tuberculosis
consisting of a 4-drug regimen (Isoniazid,
Ethambutol, Rifampicin, Pyrazinamide [HERZ]) and
IV dexamethasone (8mg q8h), and the ceftriaxone
was stopped. On the fifth day of admission, the
patient deteriorated further and developed respiratory
distress. High flow 0 2 was added to the patient's
treatment, but the patient rapidly deteriorated and
died the same day.  The likely cause of death was
uncal-tonsilar herniation due to raised intracranial
pressure.
The difficulty in interpreting CSF results is not
unique to this case.  CSF results can be very similar in
partially treated bacterial meningitis and early TBM
and making a clear diagnosis is often extremely
challenging (15). Delays in diagnosis and treatment
are major contributing factors to the high mortality
and, as a result, approximately 30% of patients with
TBM die despite anti-tuberculosis chemotherapy (16).
Even though anti-TB treatment in Uganda is free, the
free drugs at the Mulago Hospital are dispensed only
two times per week, meaning that patients presenting
on non-dispensing days must purchase their own
medication. Since NM did not present on a dispensing
day, she had to buy the initial 3 doses oftreatment.  In
Uganda, most drugs are not supplied by the hospital
and it is upon the patient to purchase their own drugs,
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making hospital stay affordable only to those with
money.
4)  Toxoplasmosis or Primary CNS Lymphoma?
DD, a 45 year-old male, presented to the Mulago
Hospital with complaints of a 2 ½ month history of
recurrent fevers, a one month history of cough and
“not speaking”, and a 3 day history of “failure to
walk” and "urinary incontinence". Due to his aphasia,
his history was obtained from his wife. He was
generally healthy and this was his first admission to
the hospital. For the first month of his fevers, he
received treatment for malaria at various private
clinics. However, the persistent fevers and lack of
improvement despite treatment with antimalarial
drugs prompted his wife to urge him to get tested from
HIV. An HIV test was done at Mulago hospital one
month prior to admission. Upon finding out that he
was HIV+, he refused to share this information with
his wife. However, after repeated pleas, he revealed
his status and never spoke from that moment on. He
refused to feed, became withdrawn, and kept himself
isolated during the one month before admission.
Three days prior to admission, he stopped walking
due to lower limb weakness, developed urinary
incontinence and constipation, all of which prompted
his wife to bring him to the Mulago Hospital casualty
department on the 6th of September. 
On presentation, the physical exam was difficult to
interpret because of DD's psychiatric presentation. He
appeared to be mildly wasted, was fully conscious
with a GCS of 15/15, with intact comprehension but
with expressive aphasia.  He had oral candidiasis, his
neck was "stiff", Kernig's sign was negative, and
papilledema was not assessed. The power in his right
and left upper limb were 5/5 and 4/5 respectively and
3/5 in both lower limbs. The tone and reflexes were
normal in the upper limbs. There was hypertonia and
hyperreflexia (3+) in both lower limbs. Toes were
down-going bilaterally and the remainder of the
physical exam was unremarkable.  He was diagnosed
with depression and subjective paraparesis with a
differential diagnosis of organic brain syndrome
secondary to opportunistic infections associated with
HIV (TBM, toxoplasmosis, CM, ABM, encephalitis).
To rule out organic brain syndrome, a lumbar
puncture was done and results revealed clear and
colourless CSF that was under moderate pressure, a
white blood cell count <5 cells/mm3, protein of 80
mg/dL, and Gram stain, India ink, ZN, VDRL, TPHA,
and culture were all negative.  The LP was therefore
undiagnostic with only mild protein elevation. His
CBC revealed lymphocytopenia corresponding to
immunosuppression associated with HIV/AIDS.
Chest x-ray and liver function tests were normal. The
working diagnosis remained depression and he was
treated with Fluoxetine (20 mg po QD).
On the 4th day of admission, weakness progressed
and became right-sided hemiparesis.  Toxoplasmosis
titers were done on the same day and came back
negative (IgG 4.1 ng/ml [>5 ng/ml being positive],
IgM index 0.37 [>0.96 being positive]). On the 7th
day of admission, weakness further progressed and
became right-sided hemiplegia. A CT scan of the head
was done on the same day and revealed a nodular,
ring-enhancing lesion in the anterior part of the left
basal ganglia with brain edema and moderately raised
intracranial pressure. There was a mid-line shift of 0.5
mm to the right with lateral ventricle compression on
the left.  The findings were suggestive of an
inflammatory process with abscess formation and a
high suspicion of toxoplasmosis.  The diagnosis post-
CT scan was cerebral toxoplasmosis with differential
diagnoses of primary CNS lymphoma and bacterial
abscess (mycotic aneurysm, tuberculoma, metastatic
lesion less likely). The patient was started on high
dose Septrin (1920 mg po q6h) for toxoplasmosis and
2 days of high dose IV steroids (8 mg dexamethasone
q8h) followed by oral prednisolone (40 mg QD) for
brain edema.  After four days of anti-toxoplasmosis
and steroid treatment, the patient remained in hospital
and the wife reported slight improvement.  However,
the patient remained aphasic with right-sided
weakness.
The case would be challenging in any setting.
Firstly, it illustrates the difficulty associated with
Figure 2. CT scan (post-contrast) of patient DD showing a nodular,
ring-enhancing lesion in the anterior part of the left basal ganglia with
accompanying brain edema and moderately raised intracranial
pressure.  There is a 0.5 mm mid-line shift with lateral ventricle
compression on the left.  The findings are suggestive of an
inflammatory process with abscess formation and a high probability
of toxoplasmosis with differential diagnoses of primary CNS
lymphoma and a bacterial abscess (less likely mycotic aneurysm,
tuberculoma, or metastatic lesion).CNS Infections 47
acceptance of serostatus due to stigmatization
associated with being HIV positive. HIV status
challenges relationships.  In this case, the husband
feared revealing his status to his wife for fear of his
wife leaving him alone with his illness.  The impact of
HIV infection on the disruption of families through
separation, divorce, and widowhood has been
examined among women in the Rakai district, Uganda
(17). The research results revealed that family
dissolution is more common among HIV-infected
women and that infected women in HIV-discordant
couples (where only one partner is positive) are
especially vulnerable to separation or divorce.  It is
very likely that DD was facing similar fears,
especially because his wife was HIV negative.
The case also demonstrates challenges in diagnosis of
psychiatric illness versus an organic process. The
patient's depressive state on admission was diagnosed
as a psychiatric illness and would have been
overlooked as such had further investigations not
been performed. Finally, the fact that a CT scan
revealed a brain lesion is only somewhat helpful.  The
fact that anti-toxoplasmosis antibody titers were
negative [they are positive in most patients either
before or at time of diagnosis (18) in part because the
tests used for measuring anti-toxoplasmosis antibody
titers have a high sensitivity and thus are positive in
most of suspected cases (19), being negative in <3-6%
of patients with toxoplasmosis (20)] and the CT scan
revealed a single lesion [toxoplasmosis usually
presents with multiple ring-enhancing lesions (21)]
questions the value of toxoplasmosis treatment.
There is, however, one report of anti-Toxoplasma
antibody negative cases with pathologically proven
disease (in 22% of patients) and single enhancing
lesions on CT (in 27% of patients) (22), providing
further evidence of the complexity of diagnosing CNS
infections in any setting, irrespective of available
diagnostic modalities.  It is important to note that if
the patient's lesion is a primary CNS lymphoma,
treatment in a resource-poor setting is limited (see 
discussion for challenges in differentiating
toxoplasmosis and primary CNS lymphoma).  At the
time of this report, the patient remains in the hospital
awaiting response to treatment.
CONCLUSION
Postmortem studies have shown that there is a high
frequency of neuropathologic abnormalities and that
there often may be mixed pathology in HIV-1 infected
patients (27). This suggests that the CNS is a frequent
target for HIV-related pathology as well as that
diagnosis is often challenging and complicated.
Diagnosis may be difficult because findings of lumbar
puncture, CT scan, and MRI are relatively
nonspecific, making diagnosis complicated in even
the most sophisticated centres (20). In resource-poor
settings, the limited availability and high associated
cost of diagnostic techniques such as CT scans, MRI,
and PCR analysis of the CSF, as well as risks
associated with brain biopsy, further limit the
probability of obtaining an accurate diagnosis,
thereby preventing prompt and specific treatment.
Therefore, an algorithmic approach, such as the one
currently being studied, to help in overcoming these
challenges may result in better treatment and outcome
as well as shorten in-hospital stays in areas where
resources are limited. 
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